# Cellular Origins

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellular-origins

- Industry: Medical Devices & Equipment
- Headquarters: Melbourn, UK
- Website: www.cellularorigins.com
- Total disclosed funding: $40M
- Latest round: Series A (Nov 24, 2025)
- Investors on record: 5

## About

Based in the UK, Cellular Origins Ltd specializes in providing advanced automation solutions for the cell therapy manufacturing sector, focusing on enhancing efficiency and precision through innovative technology.Cellular Origins Ltd, founded in 2022, is based in Melbourn, UK, and is dedicated to developing cutting-edge solutions for cell therapy manufacturing. The company has completed a Series A funding round, raising USD 40.00 mn, led by Johnson & Johnson Innovation, with participation from BGF Investment Management, Highland Europe, NYBC Ventures, and TTP Group Limited. This funding will support the company's growth initiatives and operational enhancements. The founder's history is not detailed publicly, and there are no mentions of previous companies founded by the individual.Cellular Origins specializes in the development and commercialization of its flagship product, the Constellation® ecosystem, a mobile robotic automation platform tailored specifically for the cell therapy manufacturing sector. This advanced platform integrates robotics and automation to streamline existing cell therapy processes, offering clients a fully automated, GMP-compliant solution that enhances efficiency, precision, and flexibility. Constellation enables therapy developers to scale their processes without significant alterations to their existing workflows, which is crucial for responding to the growing demand for cell therapies. The company's client base primarily includes biopharmaceutical companies engaged in the development and manufacturing of autologous and allogeneic cell therapies, particularly in regions such as North America, Europe, and parts of Asia. By partnering with leading technology providers, Cellular Origins ensures that its solutions are equipped to support the specific requirements of various therapies, ultimately bridging the gap between innovation and industrialization in cell therapy.Cellular Origins has successfully completed a USD 40.00 mn Series A funding round aimed at enhancing its operational capabilities and expanding its market reach. The company operates primarily on a B2B model, engaging directly with biopharmaceutical manufacturers who utilize the Constellation platform for their production needs. Revenue generation occurs through partnerships and collaborations with clients, providing tailored automation solutions that integrate seamlessly with their existing manufacturing processes. The pricing structure for Constellation and associated services is designed to accommodate varying scales of operation, allowing clients to choose options that best suit their production needs and growth trajectories. By delivering a coordinated solution that reduces production costs and maximizes facility efficiency, Cellular Origins positions itself as a vital partner for companies looking to meet the increasing demand for scalable and reliable cell therapies.In December 2025, Cellular Origins Ltd raised USD 40.00 mn in Series A funding to expand its team, develop additional manufacturing modules, and support the scale-up of production capabilities. The company plans to introduce new product offerings that enhance the existing Constellation platform, although specific release dates are not yet disclosed. Cellular Origins also targets expansion into new geographic markets, particularly in North America and Asia, by the end of 2026, to meet the growing demands of the cell therapy sector.

## Funding rounds

- Series A, Nov 24, 2025, $40M — Johnson & Johnson Innovation, BGF Investment Management, Highland Europe, TTP Group Limited, NYBC Ventures

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- BGF Investment Management (https://capitalatlas.ai/funds/bgf-investment-management) — Series A
- Highland Europe (https://capitalatlas.ai/funds/highland-europe) — Series A
- TTP Group Limited — Series A
- NYBC Ventures (https://capitalatlas.ai/funds/nybc-ventures) — Series A